Free Trial
ASX:IMM

Immutep (IMM) Stock Price, News & Analysis

Immutep logo

About Immutep Stock (ASX:IMM)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2.15 million shs
Average Volume
N/A
Market Capitalization
$465.79 million
P/E Ratio
N/A
Dividend Yield
6.41%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Remove Ads
Receive IMM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter.

IMM Stock News Headlines

Immutep announces first patient dosed in TACTI-004 Phase III trial
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Immutep Ltd (PRRUF) Receives a Buy from Canaccord Genuity
See More Headlines

IMM Stock Analysis - Frequently Asked Questions

Immutep Limited (ASX:IMM) posted its quarterly earnings data on Wednesday, February, 27th. The company reported $0.00 EPS for the quarter. Immutep had a negative trailing twelve-month return on equity of 34.61% and a negative net margin of 1,138.04%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immutep investors own include ICL Group (ICL), Geron (GERN), Enphase Energy (ENPH), Immutep (IMMP), Seres Therapeutics (MCRB), OPKO Health (OPK) and Albireo Pharma (ALBO).

Company Calendar

Last Earnings
2/27/2019
Today
4/04/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:IMM
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
-5.92
Net Income
$-42,720,000.00
Net Margins
-1,138.04%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.84 million
Price / Cash Flow
2.83
Book Value
A$0.16 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,450,000,000
Free Float
N/A
Market Cap
$465.79 million
Optionable
Not Optionable
Beta
1.93
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (ASX:IMM) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners